Suyash Shringarpure
@suyashss
Scientist at 23andMe. Interests: Machine learning, Genetics, Privacy
The genetic architecture of gene expression in individuals of African and European ancestry medrxiv.org/cgi/content/sh… #medRxiv
📌Publication alert: In a preprint from the @23andMeResearch team, we conducted one of the largest GWAS study of Long COVID and identified genetic links of chronic conditions with Long COVID. medrxiv.org/content/10.110…
Come join the webinar and hear about our latest update on how programs supported by genetic evidence from 23andMe improves clinical success!
Webinar: 90% of therapeutic programs in clinical trials fail. Join us Tues Aug 13 at 12pm ET to hear from Xin Wang, Ph.D. from @23andMe as she shares recent work on how the scale of genetic data and improved methods impact clinical success. Register here: bit.ly/3zWGI9y
Excited to share our latest paper, where we describe ITSN1 as a novel risk gene for Parkinson's disease! We found that rare loss-of-function variants are associated with a 10-fold increased odds of PD. As far as we know, this is the largest effect size reported for sporadic PD…
In a preprint from the @23andMeResearch team, we used Mendelian randomization to explore the genetically-predicted causal effects of Lp(a) on a range (n=489) of human traits and diseases. medrxiv.org/content/10.110…
Webinar: 90% of therapeutic programs in clinical trials fail. Join us Tues Aug 13 at 12pm ET to hear from Xin Wang, Ph.D. from @23andMe as she shares recent work on how the scale of genetic data and improved methods impact clinical success. Register here: bit.ly/3zWGI9y
New preprint from @23andMeResearch @23andMe reports 4-5x success with genetic evidence for drug trial success.
Previous papers have shown that drug targets with supporting genetic evidence can have twice the success rate when reaching clinical trials. In our most recent paper (medrxiv.org/content/10.110…), we looked at how data from @23andMe can provide additional genetic evidence. 🧵1/8